ANI Pharmaceuticals (NASDAQ:ANIP) SVP Ori Gutwerg Sells 3,162 Shares

Posted by on Aug 12th, 2026

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) SVP Ori Gutwerg sold 3,162 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $77.00, for a total value of $243,474.00. Following the transaction, the senior vice president directly owned 75,534 shares of the company’s stock, valued at $5,816,118. This represents a 4.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $74.53 on Wednesday. The company has a market cap of $1.70 billion, a price-to-earnings ratio of 16.06 and a beta of 0.44. The business has a 50 day moving average price of $81.00 and a 200 day moving average price of $79.18. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals, Inc. has a twelve month low of $70.15 and a twelve month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. During the same period in the previous year, the business posted $1.80 EPS. The company’s revenue for the quarter was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts predict that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ANIP. Advisors Asset Management Inc. acquired a new stake in ANI Pharmaceuticals during the first quarter worth $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of ANI Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock valued at $736,000 after buying an additional 470 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of ANI Pharmaceuticals by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after buying an additional 423 shares in the last quarter. Jane Street Group LLC bought a new position in shares of ANI Pharmaceuticals during the 1st quarter worth about $2,706,000. Finally, Norges Bank bought a new position in shares of ANI Pharmaceuticals during the 2nd quarter worth about $625,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ANIP has been the subject of several research analyst reports. Canaccord Genuity Group cut their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research note on Monday. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Guggenheim dropped their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a report on Monday. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, Weiss Ratings upgraded shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Five research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $105.83.

Read Our Latest Report on ANIP

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

Featured Articles

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.